Gene Therapy of Cancer

References

• Friedmann T. The evolving concept of gene therapy. Hum Gene Ther 1990; 1: 175–181
   PubMed Web of Science ®Google Scholar
• Anderson WF. Prospects for human gene therapy. Science 1984; 226: 401–409
   PubMed Web of Science ®Google Scholar
• Dzierzak EA., Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in munne bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988; 331: 35–41
   PubMed Web of Science ®Google Scholar
• Gelinas RE., Bender MA., Miller AD., Novak U. Long-term expression of the human beta-globin gene after retroviral transfer into pluripotent hematopoietic stem cells of the mouse. Adv Exp Med Biol 1989; 271: 135–148
   PubMedGoogle Scholar
• Miller AD., Eckner RJ., Jolly DJ., Friedmann T, Verma IM. Expression of a retrovirus encoding human HPRT in mice. Science 1984; 225: 630–632
   PubMed Web of Science ®Google Scholar
• Willis RC., Jolly DJ., Miller AD., et al. Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphori-bosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector. J Biol Chem 1984; 259: 7842–7849
   PubMed Web of Science ®Google Scholar
• Culver KW., Morgan RA., Osborne WR., et al. In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. Hum Gene Ther 1990; 1: 399–410
   PubMed Web of Science ®Google Scholar
• The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327–362
   PubMed Web of Science ®Google Scholar
• Kantoff PW., Kohn DB., Mitsuya H, et al. Correction of adeno-sine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1986; 83: 6563–6567
   PubMed Web of Science ®Google Scholar
• Lim B, Apperley JF., Orkin SH., Williams DA. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci USA 1989; 86: 8892–8896
   PubMed Web of Science ®Google Scholar
• Belmont JW., Henkel-Tigges J, Chang SM., et al. Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer. Nature 1986; 322(6077)385–387
   PubMed Web of Science ®Google Scholar
• McLvor RS., Goddard JM., Simonsen CC., Martin DW., Jr. Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cells. Mol Cell Biol 1985; 5: 1349–1357
   PubMed Web of Science ®Google Scholar
• Osborne WR., Miller AD. Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibro-blasts from enzyme-deficient humans. Proc Natl Acad Sci USA 1988; 85: 6851–6855
   PubMed Web of Science ®Google Scholar
• Dick JE., Magli MC., Huszar D, Phillips RA., Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long term culture reconstitution of the hematopoietic system of W/W mice. Cell 1985; 42: 71–79
   PubMed Web of Science ®Google Scholar
• Eglitis MA., Kantoff P, Gilboa E, Anderson WF. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 1985; 230: 1395–1398
   PubMed Web of Science ®Google Scholar
• Keller G, Paige C, Gilboa E, Wagner EF. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature 1985; 318: 149–154
   PubMed Web of Science ®Google Scholar
• Kantoff PW., Gillio AP., McLachlin JR., et al. Expression of human adenosine deaminase in nonhuman promates after retrovirus-mediated gene transfer. J Exp Med 1987; 166: 219–234
   PubMed Web of Science ®Google Scholar
• Freeman SM., Whartenby KA., Koeplin DS., Moolten FL., Ab-Boud CN., Abraham GN. Tumor regression when a fraction of the tumor mass contains the HSV-TK gene. J Cell Biol 1992; 16F: 47
   Google Scholar
• Nabel EG., Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285–1288
   PubMed Web of Science ®Google Scholar
• Lim CS., Chapman GD., Gammon RS., et al. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog [see comments]. Circulation 1991; 83: 2007–2011
   PubMed Web of Science ®Google Scholar
• Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1987; 84: 156–160
   PubMed Web of Science ®Google Scholar
• Wilson JM., Grossman M, Wu CH., Chowdhury NR., Wu GY., Chowdhury JR. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem 1992; 267: 963–967
   PubMed Web of Science ®Google Scholar
• Muenchau DD., Ruscetti S, Anderson WF. Sequence present in a small region of the AKV virus envelope gene determines the efficiency with which pseudotyped spleen focus-forming virus infects erythroid target cells. Virology 1992; 181: 161–166
   Web of Science ®Google Scholar
• Morgan RA., Cornetta K, Anderson WF. Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. Hum Gene Ther 1990; 1: 135–149
   PubMed Web of Science ®Google Scholar
• Topalian SL., Solomon D, Rosenberg SA. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714–3725
   PubMed Web of Science ®Google Scholar
• Rosenberg SA., Packard BS., Aebersold PM., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]. N Engl J Med 1988; 319: 1676–1680
   PubMed Web of Science ®Google Scholar
• Fisher B, Packard BS., Read EJ., et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250–261
   PubMed Web of Science ®Google Scholar
• The N2-T1L human gene transfer clinical protocol. Hum Gene Ther 1990; 1: 73–92
   PubMed Web of Science ®Google Scholar
• Cheson BD., Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Autologous bone marrow transplantation: Current status and future directions. Ann Intern Med 1989; 110: 51–65
   PubMed Web of Science ®Google Scholar
• Rill DR., Buschle M, Foreman NK., et al. Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther 1992; 3: 129–136
   PubMed Web of Science ®Google Scholar
• The University of Texas M.D. Anderson Cancer Center. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: A pilot trial. Hum Gene Ther 1991; 2: 359–376
   PubMedGoogle Scholar
• Hogge DE., Humphries DK. Gene transfer to primary normal and malignant human hematopoietic progenitors using recombinant retroviruses. Blood 1987; 69: 611–617
   PubMed Web of Science ®Google Scholar
• Brenner MK., Rill DR., Moen RC., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Morecki S, Karson E, Cornetta K, et al. Retrovirus-mediated gene transfer into CD4+ and CD8 + human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells. Cancer Immunol Immunother 1991; 32: 342–352
   PubMed Web of Science ®Google Scholar
• TNF/TIL human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 441–480
   PubMed Web of Science ®Google Scholar
• Asher AL., Mule JJ., Reichert CM., Shiloni E, Rosenberg SA. Studies of the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1992; 138: 963–974
   Google Scholar
• Rosenberg SA., Lotze MT., Yang JC., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–485
   PubMed Web of Science ®Google Scholar
• Rosenberg SA., Lotze MT., Muul LM., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Ojeifo JO., Forough R, Maciag T, Zwiebel J. Genetically-modified endothelial cells administered intravenously are incorporated into sites of active angiogenesis. J Cellular Biochem 1992; 50(Suppl 16F)
   Google Scholar
• Bubenik J, Voitenok NN., Kieler J, et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 1988; 19: 279–282
   PubMed Web of Science ®Google Scholar
• Fyfe JA., Keller PM., Furman PA., Miller RA., Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978; 253: 8721
   PubMed Web of Science ®Google Scholar
• Furman PA., McGuirt PV., Keller PM., Fyfe JA., Elion GB. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with the herpes virus genetic information. Virology 1980; 12: 420–430
   Web of Science ®Google Scholar
• Moolten FL., Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297–300
   PubMed Web of Science ®Google Scholar
• Moolten FL., Wells JM., Heyman RA., Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymi-dine kinase transgene. Hum Gene Ther 1990; 1: 125–134
   PubMed Web of Science ®Google Scholar
• Moolten FL. Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit Rev Immunol 1990; 10: 203–233
   PubMed Web of Science ®Google Scholar
• Kohn DB., Nolta JA., Weinthal J, et al. Toward gene therapy for Gaucher disease. Hum Gene Ther 1991; 2: 101–105
   PubMed Web of Science ®Google Scholar
• Short MP., Choi BC., Lee JK., Malick A, Breakefield XO., Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427–439
   PubMed Web of Science ®Google Scholar
• Takamiya Y, Short MP., Ezzeddine ZD., Moolten FL., Breakefield XO., Martuza RL. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493–503
   PubMed Web of Science ®Google Scholar
• Culver KW., Ram Z, Wallbridge S, Ishii H, Oldfield EH., Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Sorrentino BP., Brandt SJ., Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDRI. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• McLachlin JR., Eglitis MA., Ueda K, et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer [see comments]. J Natl Cancer Inst 1990; 82: 1260–1263
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Hellstom KE. In vitro demonstration of cell bound immunity against autologous MCA and plastic disc-induced mouse tumors. Science 1967; 156: 981–983
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, von Hoegen P, Heicappell R. Virus modified tumor cell vaccines for active specific immunotherapy of microme-tastases: expansion and activation of tumor-specific T cells. Prog Clin Biol Res 1989; 288: 391–399
   PubMedGoogle Scholar
• Cassel WA., Murray DR., Phillips H. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856–860
   PubMed Web of Science ®Google Scholar
• Bohle W, Schlag P, Liebrich W, et al. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus [published erratum appears in Cancer 1991 67(8):2124]. Cancer 1990; 66: 1517–1523
   PubMed Web of Science ®Google Scholar
• Pellegrino MA., Ferrone S, Reisfeld RA., Irie RF., Golub SH. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer 1977; 40: 36–41
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yoshioka T, Biebech C, Jay G. Role of the major histocompatibility complex class I antigen in tumor growth and metastasis. Annu Rev Immunol 1988; 6: 359–380
   PubMed Web of Science ®Google Scholar
• Weber JS., Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med 1987; 166: 1716
   PubMed Web of Science ®Google Scholar
• Fearon ER., Pardoll DM., Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1992; 60: 397–403
   Web of Science ®Google Scholar
• Golumbek PT., Lazenby AJ., Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820–7825
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumor-igenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Rosenberg SA., et al. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum Gene Ther 1992; 3: 57–73
   PubMedGoogle Scholar
• The revised Points to Consider: document. Hum Gene Ther 1990; 1: 93–103
   PubMedGoogle Scholar
• Epstein SL. Regulatory concerns in human gene therapy. Hum Gene Ther 1991; 2: 243–249
   PubMed Web of Science ®Google Scholar
• Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther 1990; 1: 111–123
   PubMed Web of Science ®Google Scholar
• Wolff JA., Malone RW., Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–1468
   PubMed Web of Science ®Google Scholar
• Jiao S, Acsadi G, Jani A, Feigner PL., Wolff JA. Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp Neurol 1992; 115: 400–413
   PubMed Web of Science ®Google Scholar
• Stratford-Perricaudet LD., Levrero M, Chasse JF., Perricaudet M, Briand P. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241–256
   PubMed Web of Science ®Google Scholar
• Samulski RJ., Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBOJ 1991; 10: 3941–3950
   PubMed Web of Science ®Google Scholar
• Bassin RH., Tuttle N, Fischinger PJ. Rapid cell culture assay technique for murine leukemia viruses. Nature 1971; 229: 564–566
   PubMed Web of Science ®Google Scholar
• Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988; 85: 6460–6464
   PubMed Web of Science ®Google Scholar
• Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol 1988; 62: 1120–1124
   PubMed Web of Science ®Google Scholar
• Markowitz D, Goff S, Bank A. Construction of a safe and efficient retrovirus packaging cell line. Adv Exp Med Biol 1988; 241: 35–40
   PubMedGoogle Scholar
• Miller AD., Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980–982; 984–986
   PubMed Web of Science ®Google Scholar
• Cornetta K, Moen RC., Culver K, et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1990; 1: 15–30
   PubMed Web of Science ®Google Scholar
• Donahue RE., Kessler SW., Bodine DM., et al. In vivo evaluation of gene transfer to priate CD34+ cells. J Cell Biochem 1992; 16F: 46
   Google Scholar
• Whartenby KA., Zwiebel JA., Vonderhaar BK., Freeman SM., Abraham GN. Analysis of transformed cells after transduction with retroviral vectors. J Cell Biol 1992; 16F: 52
   Google Scholar
• Yu SF., von Ruden T, Kantoff PW., et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194–3198
   PubMed Web of Science ®Google Scholar